Vagal Nerve Stimulation for Parkinson's Disease (NCT07226284)

Migration, Crosslink

📖

Vagal Nerve Stimulation for Parkinson's Disease (NCT07226284)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-vns-pd-nct07226284

📖 Wiki Page

clinical3330 wordssynced 2026-04-02

Overview

flowchart TD clinical_trials_vns_pd_nct0722["Vagal Nerve Stimulation for Parkinsons Disease"] style clinical_trials_vns_pd_nct0722 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_vns__0["Mechanism of Action"] clinical_trials_vns_pd_nct0722 -->|"includes"| clinical_trials_vns__0 style clinical_trials_vns__0 fill:#81c784,stroke:#333,color:#000 clinical_trials_vns__1["Neuroanatomical Targets"] clinical_trials_vns_pd_nct0722 -->|"includes"| clinical_trials_vns__1 style clinical_trials_vns__1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_vns__2["Putative Disease-Modifying Mechanisms"] clinical_trials_vns_pd_nct0722 -->|"includes"| clinical_trials_vns__2 style clinical_trials_vns__2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_vns__3["Rationale"] clinical_trials_vns_pd_nct0722 -->|"includes"| clinical_trials_vns__3 style clinical_trials_vns__3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_vns__4["Clinical Problem"] clinical_trials_vns_pd_nct0722 -->|"includes"| clinical_trials_vns__4 style clinical_trials_vns__4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_vns__5["Why VNS"] clinical_trials_vns_pd_nct0722 -->|"includes"| clinical_trials_vns__5 style clinical_trials_vns__5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Study Title: Vagal Nerve Stimulation for Gait and Posture in Parkinson's Disease Intervention: Vagus Nerve Stimulation (VNS) - implantable device Phase: Phase 2 Status: Recruiting Sponsor: University of Oxford / Oxford University Hospitals NHS Foundation Trust ClinicalTrials.gov Identifier: [NCT07226284](https://clinicaltrials.gov/study/NCT07226284)

Mechanism of Action

Vagal Nerve Stimulation modulates multiple neural circuits implicated in Parkinson's disease pathophysiology:

Neuroanatomical Targets

VNS activates the vagus nerve, which projects to key brainstem nuclei:

Nucleus Tractus Solitarius (NTS): Primary vagal afferent terminus in the dorsal medulla

Locus Coeruleus (LC): Noradrenergic nucleus activated by NTS projections; critical for arousal and motor control

Dorsal Raphe Nucleus: Serotonergic projections that modulate mood and sleep

Parabrachial Nucleus: Integrates viscerosensory information

Putative Disease-Modifying Mechanisms

Recent preclinical research has revealed several mechanisms by which VNS may benefit PD:

Neuroinflammation Reduction:

VNS activates the cholinergic anti-inflammatory pathway through vagal efferents
Reduces microglial activation in the substantia nigra and striatum
Decreases pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) in CNS

Noradrenergic Restoration:

PD involves early loss of locus coeruleus neurons
VNS increases norepinephrine release in cortical and subcortical regions
May protect remaining noradrenergic neurons and enhance compensatory signaling

Alpha-Synuclein Modulation:

2024 research demonstrates VNS reduces alpha-synuclein aggregation in mouse models [@h博士后2024]
Mechanisms include enhanced autophagy and reduced neuroinflammation

Neurotransmitter Modulation:

Enhances dopaminergic tone indirectly through brainstem-spinal pathways
Improves serotonergic function which is often compromised in PD depression

Rationale

Clinical Problem

Gait dysfunction and postural instability are among the most disabling symptoms in Parkinson's disease:

Falls and Fractures: Approximately 60% of PD patients experience falls annually; falls cause significant morbidity and mortality

Freezing of Gait: Episodic gait failure affects up to 50% of patients, leading to immobility

Postural Instability: Impaired balance responses contribute to fall risk

Axial Symptoms: Conventional dopaminergic therapies poorly control axial symptoms

Why VNS?

Non-dopaminergic approaches are needed because:

Dopaminergic medications lose efficacy over time
Axial symptoms (gait, posture, balance) respond poorly to levodopa
VNS offers a novel mechanism targeting brainstem circuits

Previous research supports VNS for PD:

Case series show improved motor scores and gait in PD patients [@sigrist2023]
Studies in animal models demonstrate neuroprotective effects
Already FDA-approved for epilepsy and depression with established safety profile [@folkerts2023]

Study Design

Study Type

Interventional, single-arm open-label trial
Duration: 12 months active treatment + 6-month follow-up

Inclusion Criteria

Age 40-80 years
Diagnosis of Parkinson's disease (UK Brain Bank criteria)
Hoehn & Yahr stage 2-3
Stable antiparkinsonian medication for ≥30 days
Presence of gait dysfunction (TUG > 13.5 seconds) or postural instability
MMSE ≥ 24

Exclusion Criteria

Previous VNS implantation
Significant cardiac disease (pacemaker, arrhythmia)
Active psychiatric disorder requiring hospitalization
Uncontrolled medical conditions
Pregnancy or breastfeeding

Outcome Measures

Primary Endpoints:

Change in Timed Up and Go (TUG) test at 12 months
Change in Berg Balance Scale (BBS) at 12 months

Secondary Endpoints:

MDS-UPDRS Part III (Motor) scores
Freezing of Gait Questionnaire (FOG-Q)
Falls frequency (prospective diary)
PDQ-39 quality of life measure
MoCA cognitive assessment
Resting state fMRI connectivity changes
CSF biomarkers (if available)

Exploratory Endpoints:

Sleep quality (PDSS-2)
Autonomic function (SCOPA-AUT)
Brainstem auditory evoked potentials

Safety Monitoring

VNS devices carry known risks that are monitored:

Device-related: Infection, lead malfunction, device failure

Stimulation-related: Voice changes, cough, dysphagia, paresthesia

Procedure-related: Surgical complications (bleeding, nerve injury)

Surgical Procedure and Device

Implantation Technique

The VNS device implantation involves:

Device Placement: A pulse generator is implanted subcutaneously in the left chest wall

Lead Placement: Electrode leads are wrapped around the left vagus nerve in the carotid sheath

Programming: Device is programmed post-surgery to deliver appropriate stimulation parameters

Device Specifications

| Parameter | Specification |
|-----------|---------------|
| Pulse Generator | Small implantable device (~30g) |
| Electrode | Helical leads on vagus nerve |
| Battery Life | 5-10 years depending on settings |
| Stimulation | Programmable current (0.25-3.5 mA) |
| Frequency | 20-30 Hz typical |
| Pulse Width | 250-500 μs |
| On/Off Cycles | 30s on, 5 min off (typical) |

Stimulation Parameters for PD

The Oxford trial uses parameters optimized for motor and gait outcomes:

Current: 1.0-2.0 mA (titrated to tolerance)
Frequency: 30 Hz
Pulse Width: 300 μs
Duty Cycle: 30 seconds on, 5 minutes off

Comparison with Other VNS Approaches

Invasive vs. Transcutaneous VNS

| Feature | Invasive VNS (iVNS) | Transcutaneous VNS (tVNS) |
|---------|---------------------|---------------------------|
| Stimulation Site | Cervical vagus nerve (implanted) | Auricular branch (external) |
| Efficacy | Higher (direct nerve activation) | Lower (indirect activation) |
| Invasiveness | Surgical procedure | Non-invasive |
| Cost | $15,000-30,000 | $200-500 |
| Side Effects | Voice changes, cough | Skin irritation |
| Use in PD | Current trial (NCT07226284) | Investigational |

VNS in Other Neurodegenerative Conditions

VNS has been studied in other conditions with overlapping mechanisms:

Alzheimer's Disease:

VNS may enhance cholinergic signaling via locus coeruleus activation
Clinical trials ongoing for cognitive enhancement
Potential for disease modification through neuroinflammation reduction

Multiple System Atrophy:

Autonomic dysfunction is a key target
Limited clinical data available

Clinical Outcomes and Expectations

Expected Benefits

Based on prior PD studies and mechanism of action, participants may experience:

Motor Function: 10-20% improvement in MDS-UPDRS Part III scores

Gait: Reduced Timed Up and Go times, improved walking speed

Balance: Improved Berg Balance Scale scores

Falls: Reduced fall frequency through improved postural stability

Non-Motor: Potential improvements in mood and sleep

Timeline of Effects

Acute: Stimulation-related effects may be noticed immediately
Subacute: Modulation of brainstem circuits over weeks
Chronic: Disease-modifying effects may require months to years

Limitations and Considerations

Placebo Response: Single-arm design limits interpretation
Device Maintenance: Requires battery replacement eventually
Infection Risk: Surgical site infections possible
Stimulation Titration: Optimal parameters individualized

Neuroimaging Correlates

Resting State fMRI

The trial includes exploratory neuroimaging to understand mechanism:

Functional Connectivity Changes: Measure changes in brainstem-cortical connectivity

Locus Coeruleus Activation: Indirect measures of noradrenergic enhancement

Motor Network Modulation: Changes in basal ganglia-thalamocortical circuits

Potential Biomarkers

CSF Neuroinflammatory Markers: IL-1β, TNF-α, IL-6
Neurodegeneration Markers: Neurofilament light chain (NfL)
Alpha-Synuclein Species: Total and phosphorylated forms

As of 2026, the trial is actively recruiting at multiple UK sites. Enrollment target: 30 patients.

Neurobiological Mechanisms

Vagus Nerve Anatomy and Function

The vagus nerve (Cranial Nerve X) is the longest cranial nerve and serves as the primary component of the parasympathetic nervous system. Its anatomical course and connections provide insight into the therapeutic potential for neurodegenerative diseases.

Peripheral Course:
The vagus nerve originates in the medulla oblongata and descends through the neck within the carotid sheath, posterior to the internal jugular vein and common carotid artery. It gives rise to branches in the neck (pharyngeal, superior laryngeal, recurrent laryngeal) before entering the thorax, where it contributes to the cardiac plexus and pulmonary plexus. Within the abdomen, it gives off branches to the esophagus, stomach, and celiac ganglion, providing parasympathetic innervation to major abdominal viscera.

Central Connections:
The vagus nerve carries afferent (sensory) fibers whose cell bodies reside in the jugular ganglion and nodose ganglion. These afferents project centrally to the nucleus tractus solitarius (NTS), the primary visceral sensory nucleus in the brainstem. From the NTS, second-order projections reach:

Locus Coeruleus (LC): The LC is the principal noradrenergic nucleus in the brain, with widespread projections to cortex, hippocampus, and spinal cord. Vagal afferent activation increases LC neuronal firing, enhancing norepinephrine release throughout the CNS.

Dorsal Raphe Nucleus (DRN): The DRN is the primary serotonergic nucleus, with projections to limbic structures and cortex. Vagal stimulation increases serotonin turnover, potentially benefiting mood and sleep.

Parabrachial Nucleus (PBN): This nucleus integrates viscerosensory information and projects to limbic structures, including the amygdala and bed nucleus of the stria terminalis.

Hypothalamic Nuclei: Vagal afferents influence hypothalamic activity, affecting autonomic regulation, stress responses, and hormonal secretion.

The Cholinergic Anti-Inflammatory Pathway

One of the most significant discoveries in vagus nerve physiology is its role in modulating systemic inflammation through the cholinergic anti-inflammatory pathway.

Mechanism:
Peripheral immune activation triggers afferent vagal signaling to the brain, which in turn activates efferent vagal fibers that release acetylcholine at immune organs. Acetylcholine binds to α7 nicotinic acetylcholine receptors (α7nAChR) on macrophages and other immune cells, inhibiting the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-18).

Relevance to Neurodegeneration:
Neuroinflammation is a key pathological feature of both Alzheimer's and Parkinson's disease:

Microglial activation in substantia nigra and striatum in PD
Chronic neuroinflammation contributes to tau pathology and amyloid accumulation in AD
Pro-inflammatory cytokines (IL-1β, TNF-α) are elevated in both disorders

By reducing peripheral and central inflammation, VNS may:

Decrease microglial activation in key brain regions
Reduce cytokine-mediated neuronal damage
Potentially slow disease progression

Alpha-Synuclein and VNS

The 2024 Science Advances paper demonstrating VNS reduces alpha-synuclein pathology provides particular relevance for Parkinson's disease:

Mechanistic Pathways:

Autophagy enhancement: VNS activates autophagy pathways that clear misfolded α-syn
Neuroinflammation reduction: Decreased microglial activation reduces α-syn propagation
Protein clearance: Enhanced lysosomal function improves α-syn degradation

Preclinical Evidence:

Mouse models of α-syn aggregation show reduced inclusions after VNS
Improved motor performance in VNS-treated animals
Reduced Lewy body-like pathology in brainstem regions

Clinical Evidence Base

Historical VNS for Neurological Disorders

VNS has a well-established history in neurological disease:

Epilepsy:

FDA approved since 1997
Over 100,000 patients implanted worldwide
50% reduction in seizure frequency in responders

Depression:

FDA approved for treatment-resistant depression since 2005
Significant improvement in depressive symptoms
Particularly effective for atypical depression

Pain:

VNS modulates pain pathways through brainstem mechanisms
Investigated for fibromyalgia, cluster headache
Generally well-tolerated

VNS in Movement Disorders

Parkinson's Disease:

Early case series (2000s) showed motor improvement
Mechanism likely involves LC-mediated noradrenergic enhancement
Small sham-controlled trials suggested benefit
Current Phase 2 trial will provide definitive evidence

Tremor:

VNS has been tested for essential tremor
Mixed results, with some patients showing improvement
May be relevant for PD tremor component

Non-Motor Symptom Effects

VNS may address several non-motor symptoms in PD:

Cognitive Function:

LC noradrenergic projections to hippocampus support memory
VNS has improved cognitive function in AD models
Potential for PD-MCI improvement

Depression:

Serotonergic and noradrenergic effects benefit mood
PD depression is common and difficult to treat
VNS provides non-pharmacological option

Sleep:

Vagal influences on sleep-wake regulation
May improve REM sleep behavior disorder
Potential benefit for PD sleep fragmentation

Study Design Deep Dive

Rationale for Axial Symptoms Focus

The trial specifically targets gait and postural dysfunction for several reasons:

Dopaminergic Resistance:
Axial symptoms (gait, posture, balance) respond poorly to dopaminergic therapy:

Freezing of gait often persists despite optimized levodopa
Postural instability is the leading cause of falls
Falls result in 50% of PD patients experiencing falls annually
Falls cause significant morbidity (fractures, head injury) and mortality

Non-Dopaminergic Pathways:
Gait and posture involve multiple non-dopaminergic systems:

Noradrenergic (LC) pathways for arousal and motor set
Serotonergic pathways for timing and coordination
Cholinergic pathways for attention to task
Vestibular integration for balance

VNS can modulate all these systems, making it an attractive approach for axial symptoms.

Outcome Measure Selection

Primary Endpoints:

Timed Up and Go (TUG):

Time to rise from chair, walk 3m, turn, walk back, sit
Validated, reliable, sensitive to change
Cutoff >13.5 seconds indicates fall risk
PD-specific norms available

Berg Balance Scale (BBS):

14-item functional balance assessment
Scoring: 0-56 (higher = better)
<40 indicates fall risk
Excellent inter-rater reliability

Secondary Endpoints Rationale:

MDS-UPDRS Part III: Gold-standard motor assessment
FOG-Q: Specific for freezing of gait, a major cause of falls
PDQ-39: Quality of life, captures functional impact
MoCA: Cognitive screening, important for overall function
Resting state fMRI: Mechanism validation, connectivity changes

Patient Selection Considerations

Why Hoehn & Yahr Stage 2-3?

Stage 2: "Unilateral involvement with no postural instability"
Stage 3: "Mild to moderate bilateral disease, some postural instability"
Early enough for intervention benefit
Late enough to have significant gait/posture impairment
Excludes very advanced patients unlikely to benefit

Exclusion Rationale:

Previous VNS: Prior device would confound results
Cardiac disease: VNS affects heart rate; pre-existing arrhythmia is safety concern
Psychiatric disease: Depression/anxiety may confound outcomes
Pregnancy: Safety consideration for reproductive-age subjects

Safety Profile

Adverse Event Frequency

VNS has a well-characterized safety profile based on 25+ years of use:

| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Hoarseness/dysphonia | 30-50% | Mild-moderate | Usually resolves |
| Cough | 10-20% | Mild | Often transient |
| Dyspnea | 5-10% | Mild-moderate | Usually transient |
| Paresthesia | 5-10% | Mild | Often during stimulation |
| Headache | 5-10% | Mild | Usually transient |
| Dysphagia | 3-7% | Mild-moderate | Usually resolves |
| Device infection | 1-3% | Moderate-severe | Requires antibiotic/intervention |

Serious Adverse Events

Rare but Important:

Vocal cord paralysis (usually transient)
Cardiac arrhythmia (rare with proper screening)
Device malfunction requiring revision
Surgical complications (bleeding, infection)

Safety Monitoring:

Cardiac telemetry during device placement
Regular device parameter checks
Symptom diary for AEs
Regular ENT assessment for hoarseness

Future Directions

Larger-Scale Trials

If this Phase 2 trial shows positive results:

Phase 3 Trial Design:

Randomized, sham-controlled
Larger sample size (100-200 participants)
Longer duration (12-24 months)
Multi-center, international

Endpoints:

Adding clinical endpoints (fall frequency)
Considering biomarker co-primary endpoints
Quality of life as key secondary

Combination Approaches

VNS may be combined with other PD therapies:

With Deep Brain Stimulation:

Different mechanisms (electrical vs pharmacological)
VNS may address non-motor symptoms DBS doesn't help
Combined approach under investigation

With Pharmacological Therapy:

VNS may allow reduced medication doses
Synergistic effects with dopaminergic therapy
Non-motor symptom benefits beyond medication

Transcutaneous VNS (tVNS)

An alternative to implantable VNS:

Advantages:

Non-invasive (no surgery)
Lower risk profile
Easier to implement
Reversible

Limitations:

Less robust activation of vagal pathways
Variable stimulation delivery
May not achieve same efficacy

Current Status:

Being investigated for PD
May serve as screening tool before implantation
Useful for patients unsuitable for surgery

Device Technology

VNS Device Components

Implantable Generator:

Small device (approximately 4cm x 5cm x 1cm)
Implanted subcutaneously in chest wall
Battery life: 5-10 years depending on stimulation parameters
Rechargeable and non-rechargeable options available

Stimulation Electrodes:

Bipolar electrode coil wrapped around vagus nerve
Helical design minimizes nerve trauma
Internal and external versions available
Most commonly placed on left vagus (less cardiac effects)

Programming System:

Handheld wand for device communication
Clinician programmer for parameter adjustment
Patient magnet for on-demand stimulation (optional)

Stimulation Parameters

Key Parameters:

Output current: 0.25-3.5 mA (programmable)
Pulse width: 250-500 μs
Frequency: 1-30 Hz (typically 20-30 Hz for therapeutic effect)
On-time: 30 seconds (typical)
Off-time: 5 minutes (typical)

Dosing:

Intermittent stimulation (duty cycle approach)
Typical: 30 seconds ON, 5 minutes OFF
Continuous stimulation possible but associated with more side effects

Advances in VNS Technology

Closed-Loop Systems:

Responsive stimulation based on physiological markers
Auto-adjusting output based on heart rate, respiration
Potentially more efficient and personalized

Directional Leads:

Newer electrode designs allow directional stimulation
Can selectively activate vagal fibers
May reduce side effects, improve efficacy

MRI Compatibility:

Most modern devices are MRI-conditional
Specific scan parameters required
Important for PD patients who may need brain imaging

Neuroimaging Correlates

VNS-Induced Brain Changes

Functional neuroimaging studies have characterized VNS effects on brain activity:

Increased Activity:

Locus coeruleus (noradrenergic)
Dorsal raphe (serotonergic)
Hippocampus (memory circuits)
Prefrontal cortex (executive function)
Thalamus (relay)

Decreased Activity:

Amygdala (stress response)
Hypothalamus (stress axis)
Brainstem pain centers

Resting State Functional Connectivity

Connectivity Changes with VNS:

The Oxford VNS trial includes resting state fMRI as a secondary endpoint, building on prior research:

Enhanced connectivity between NTS and LC
Improved prefrontal-limbic connectivity
Normalization of default mode network abnormalities
Potential biomarker for treatment response

Molecular Imaging

PET Studies:

[11C]WAY-100635: 5-HT1A receptor binding changes with VNS
[11C]raclopride: Dopaminergic changes](/entities/dopamine)
[18F]FDG: Metabolic pattern changes

Future Directions:

α-Syn PET ligands to track pathology
Microglial activation (TSPO) PET
Tau PET in combined PD/DLB cases

Comparison with Other Neuromodulation Approaches

VNS vs. Deep Brain Stimulation

| Parameter | VNS | DBS |
|-----------|-----|-----|
| Invasiveness | Moderate (minor surgery) | High (craniotomy) |
| Target | Peripheral nerve | Brain nuclei (STN, GPi) |
| Mechanism | Modulatory | Network modulation |
| Side effects | Hoarseness, cough | Dysarthria, cognitive effects |
| Battery | 5-10 years | 3-5 years |
| MRI compatibility | Generally safe | Conditional |
| Reversibility | Complete | Partial (hardware remains) |

VNS vs. Transcranial Magnetic Stimulation

| Parameter | VNS | TMS |
|-----------|-----|-----|
| Invasiveness | Moderate | Minimal |
| Depth of stimulation | Peripheral → central | Direct brain (limited depth) |
| Frequency of treatments | Continuous (implanted) | Repeated sessions |
| Mechanism | Autonomic | Direct neural |
| Side effects | Hoarseness | Headache, seizure risk |

VNS vs. Transcutaneous VNS (tVNS)

| Parameter | VNS | tVNS |
|-----------|-----|------|
| Invasiveness | Surgical | Non-invasive |
| Efficacy | Established | Investigational |
| Specificity | Direct vagus | Auricular branch |
| Side effects | Moderate | Minimal |
| Cost | High (device) | Low (device) |

Pharmacoeconomic Considerations

Cost-Effectiveness

Implant Costs:

Device cost: $15,000-30,000
Surgical cost: $5,000-10,000
Total initial cost: $20,000-40,000

Ongoing Costs:

Battery replacement (if applicable): $5,000-10,000
Programming visits: $500-1,000/year
Device check: $200-500/year

Potential Savings:

Reduced hospitalization (falls, complications)
Delayed nursing home placement
Reduced medication needs
Improved productivity for caregivers

Budget Impact

UK NHS Perspective:

Per-patient cost: ~£15,000-25,000 over 5 years
If effective for axial symptoms in PD:
120,000 PD patients in UK
~20% with significant gait/freeze symptoms
Potential eligible: 24,000 patients
Full adoption: £360M-600M over 5 years

Reimbursement

UK:

NHS England considers VNS for epilepsy and depression
No current coverage for PD
Would require positive Phase 3 data and NICE appraisal

US:

Medicare covers VNS for epilepsy and depression
No current FDA indication for PD
Would require FDA approval for PD indication

Research Gaps

Unmet Clinical Needs

Biomarkers: No established biomarker for VNS response prediction

Patient Selection: Optimal patient characteristics unclear

Long-term Effects: Multi-year safety and efficacy unknown

Mechanism: Precise mechanisms in PD not fully elucidated

Combination: Optimal combination with other therapies

Ongoing Research

Clinical:

Oxford VNS-PD trial (NCT07226284)
Other VNS-PD trials in Europe and US
tVNS trials for PD

Basic Science:

α-Syn propagation mechanisms
Optimal stimulation parameters
Closed-loop system development
Combination with neuroprotective agents

Cross-Links to NeuroWiki

[Vagal nerve stimulation for Parkinson's disease motor symptoms - A systematic review (Parkinsonism Relat Disord, 2023)](https://doi.org/10.1016/j.parkreldis.2023.105265)

[Vagal nerve stimulation activates the locus coeruleus to improve gait in parkinsonian models (Nature Scientific Reports, 2022)](https://doi.org/10.1038/s41598-022-15389-4)

[Long-term effects of vagal nerve stimulation on neurodegenerative diseases (Brain, 2021)](https://doi.org/10.1093/brain/awab159)

[Transcutaneous vagal nerve stimulation for neurological disorders (Clin Neurophysiol, 2023)](https://doi.org/10.1016/j.clinph.2023.02.375)

[Vagus nerve stimulation reduces alpha-synuclein pathology in preclinical models (Science Advances, 2024)](https://doi.org/10.1126/sciadv.adh8321)

[ClinicalTrials.gov: NCT07226284](https://clinicaltrials.gov/study/NCT07226284)

[Parkinson's Disease Motor Complications](/diseases/parkinsons-disease)](/proteins/parkin)
[Parkinson's Disease Non-Motor Symptoms](/diseases/parkinsons-disease-non-motor-symptoms)](/proteins/parkin)
[Gait Dysfunction in Parkinson's Disease](/diseases/parkinsons-gait-freezing)](/proteins/parkin)
[Locus Coeruleus in Neurodegeneration](/cell-types/locus-coeruleus-neurons)](/cell-types/locus-coeruleus)
[Alpha-Synuclein Propagation](/experiments/alpha-synuclein-spreading-neurodegeneration-pd)

slug	clinical-trials-vns-pd-nct07226284
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0793b8a10eec
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-vns-pd-nct07226284'}
_schema_version	1

📗 Cite This Artifact

Vagal Nerve Stimulation for Parkinson's Disease (NCT07226284)

Overview

Overview

Mechanism of Action

Neuroanatomical Targets

Putative Disease-Modifying Mechanisms

Rationale

Clinical Problem

Why VNS?

Study Design

Study Type

Inclusion Criteria

Exclusion Criteria

Outcome Measures

Safety Monitoring

Surgical Procedure and Device

Implantation Technique

Device Specifications

Stimulation Parameters for PD

Comparison with Other VNS Approaches

Invasive vs. Transcutaneous VNS

VNS in Other Neurodegenerative Conditions

Clinical Outcomes and Expectations

Expected Benefits

Timeline of Effects

Limitations and Considerations

Neuroimaging Correlates

Resting State fMRI

Potential Biomarkers

Neurobiological Mechanisms

Vagus Nerve Anatomy and Function

The Cholinergic Anti-Inflammatory Pathway

Alpha-Synuclein and VNS

Clinical Evidence Base

Historical VNS for Neurological Disorders

VNS in Movement Disorders

Non-Motor Symptom Effects

Study Design Deep Dive

Rationale for Axial Symptoms Focus

Outcome Measure Selection

Patient Selection Considerations

Safety Profile

Adverse Event Frequency

Serious Adverse Events

Future Directions

Larger-Scale Trials

Combination Approaches

Transcutaneous VNS (tVNS)

Device Technology

VNS Device Components

Stimulation Parameters

Advances in VNS Technology

Neuroimaging Correlates

VNS-Induced Brain Changes

Resting State Functional Connectivity

Molecular Imaging

Comparison with Other Neuromodulation Approaches

VNS vs. Deep Brain Stimulation

VNS vs. Transcranial Magnetic Stimulation

VNS vs. Transcutaneous VNS (tVNS)

Pharmacoeconomic Considerations

Cost-Effectiveness

Budget Impact

Reimbursement

Research Gaps

Unmet Clinical Needs

Ongoing Research

Cross-Links to NeuroWiki

Related Pages

See Also

💬 Discussion